Eli Lilly Revenue Rises on GLP-1 Demand

The stock action shows investors still want exposure to that thesis, even after a sharp run-up and recent volatility. Lilly shares are trading around $1,115, well above their 200-day moving average near $1,026, though the 50-day average sits closer to $1,151, suggesting the recent pullback has cooled momentum without breaking the longer-term trend. Conventional RSI readings near 42 point to a reset from overbought levels rather than a collapse in conviction.

The broader investment story is bigger than one quarterly print. GLP-1 demand is creating a secular manufacturing and supply-chain buildout, from active pharmaceutical ingredients to fill-finish capacity and cold-chain logistics. That is why the winners extend beyond Lilly itself. Contract drugmakers, packaging suppliers, device makers and even logistics firms stand to benefit as the industry races to meet a demand curve that still looks under-penetrated relative to the size of the obesity population.

Novo Nordisk remains the clearest rival and the market’s other main barometer for this trade. Its shares, around $44, have been battered over the past year, reflecting intense skepticism about execution, competition and pricing, even as its own GLP-1 sales continue to grow. Pfizer, by contrast, remains a cautionary tale: it has money, scale and scientific talent, but it has yet to prove it can capture the same level of enthusiasm or commercial momentum in obesity and metabolic care.

The macro backdrop also helps explain why the market keeps rewarding GLP-1 leaders. In an environment where healthcare remains one of the few sectors with genuinely durable volume growth, investors are paying up for companies that can expand revenues without depending on cyclical demand. Add in the powerful follow-on demand from payers and patients — including long-term use, broader indications and international rollout — and the obesity market starts to look less like a niche drug category and more like a new platform for years of earnings compounding.

For investors, the key is not just owning the obvious leader, but recognizing the second-order beneficiaries before the consensus fully prices them in. Lilly remains the anchor trade, but the bigger opportunity may be in the infrastructure and supply-chain names that get paid every time the GLP-1 market expands. The market may already understand the headline growth story; it still underestimates how much capital will be spent to support it.